ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Utilizing Caenorhabditis Elegans as a Rapid and Precise Model for Assessing Amphetamine-Type Stimulants: A Novel Approach to Evaluating New Psychoactive Substances Activity and Mechanisms.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advances in drug addiction research usingFrontiers in cell and developmental biology · 2026Review
- Utilizing Caenorhabditis Elegans as a Rapid and Precise Model for Assessing Amphetamine-Type Stimulants: A Novel Approach to Evaluating New Psychoactive Substances Activity and Mechanisms.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The surge of new psychoactive substances (NPS) poses significant public health challenges due to their unregulated status and diverse effects. However, existing in vivo models for evaluating their activities are limited. To address this gap, this study utilizes the model organism Caenorhabditis elegans (C. elegans) to evaluate the activity of amphetamine-type stimulants (ATS) and their analogs. The swimming-induced paralysis (SWIP) assay is employed to measure the acute responses of C. elegans to various ATS, including amphetamine (AMPH), methamphetamine (METH), 3,4-methylenedioxymethamphetamine (MDMA) and their enantiomers. The findings reveal distinct responses in wild-type and mutant C. elegans, highlighting the roles of dopaminergic and serotonergic pathways, particularly DOP-3 and SER-4 receptors. The assay also revealed that C. elegans can distinguish between the chiral forms of ATS. Additionally, structural activity relationships (SAR) are observed, with meta-R amphetamines showing more pronounced effects than ortho-R and para-R analogs. This study demonstrates the utility of C. elegans in rapidly assessing ATS activity and toxicity, providing a cost-effective and precise method for high-throughput testing of NPS. These results contribute to a better understanding of ATS pharmacology and offer a valuable framework for future research and potential regulatory applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.